Abbott Laboratories $ABT Shares Sold by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. reduced its stake in Abbott Laboratories (NYSE:ABT) by 62.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,970 shares of the healthcare product maker’s stock after selling 6,728 shares during the period. Roman Butler Fullerton & Co.’s holdings in Abbott Laboratories were worth $411,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ABT. Meadow Creek Wealth Advisors LLC boosted its holdings in shares of Abbott Laboratories by 12.8% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 4,141 shares of the healthcare product maker’s stock valued at $425,000 after buying an additional 471 shares in the last quarter. Peterson Wealth Services raised its stake in Abbott Laboratories by 22.8% during the 1st quarter. Peterson Wealth Services now owns 2,023 shares of the healthcare product maker’s stock worth $208,000 after acquiring an additional 376 shares in the last quarter. Griffin Asset Management Inc. lifted its position in Abbott Laboratories by 10.1% in the first quarter. Griffin Asset Management Inc. now owns 65,442 shares of the healthcare product maker’s stock valued at $6,719,000 after acquiring an additional 6,023 shares during the last quarter. Main Street Research LLC lifted its position in Abbott Laboratories by 5.6% in the first quarter. Main Street Research LLC now owns 3,859 shares of the healthcare product maker’s stock valued at $396,000 after acquiring an additional 205 shares during the last quarter. Finally, First Horizon Corp boosted its stake in Abbott Laboratories by 38.4% in the first quarter. First Horizon Corp now owns 91,246 shares of the healthcare product maker’s stock valued at $9,368,000 after acquiring an additional 25,296 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. UBS Group cut their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Citigroup dropped their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Jefferies Financial Group cut their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Oppenheimer decreased their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.42.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded down $0.42 during midday trading on Friday, reaching $93.97. 6,911,805 shares of the company were exchanged, compared to its average volume of 12,569,929. The stock has a market cap of $163.69 billion, a P/E ratio of 26.32, a PEG ratio of 1.63 and a beta of 0.61. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The stock has a fifty day simple moving average of $89.21 and a 200 day simple moving average of $103.24. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the business earned $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.